These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

849 related articles for article (PubMed ID: 15762770)

  • 1. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.
    Zhou S; Chan E; Lim LY; Boelsterli UA; Li SC; Wang J; Zhang Q; Huang M; Xu A
    Curr Drug Metab; 2004 Oct; 5(5):415-42. PubMed ID: 15544435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.
    Zhou SF
    Curr Drug Metab; 2008 May; 9(4):310-22. PubMed ID: 18473749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK; Spence JD; Bailey DG
    Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
    Lim HK; Duczak N; Brougham L; Elliot M; Patel K; Chan K
    Drug Metab Dispos; 2005 Aug; 33(8):1211-9. PubMed ID: 15860655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.
    Zhou SF
    Curr Pharm Des; 2008; 14(10):990-1000. PubMed ID: 18473851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
    Chan WK; Delucchi AB
    Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
    Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
    Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
    Mueck W; Kubitza D; Becka M
    Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
    Potęga A; Fedejko-Kap B; Mazerska Z
    Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.
    Mayhew BS; Jones DR; Hall SD
    Drug Metab Dispos; 2000 Sep; 28(9):1031-7. PubMed ID: 10950845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress curve mechanistic modeling approach for assessing time-dependent inhibition of CYP3A4.
    Burt HJ; Pertinez H; Säll C; Collins C; Hyland R; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Sep; 40(9):1658-67. PubMed ID: 22621802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.
    Zhou S; Chan E; Li X; Huang M
    Ther Clin Risk Manag; 2005 Mar; 1(1):3-13. PubMed ID: 18360537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.